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Objective: The aim of this study was to search for genes/variants that modify the effect of LRRK2 mutations in terms of
penetrance and age-at-onset of Parkinson’s disease.
Methods: We performed the first genomewide association study of penetrance and age-at-onset of Parkinson’s dis-
ease in LRRK2 mutation carriers (776 cases and 1,103 non-cases at their last evaluation). Cox proportional hazard
models and linear mixed models were used to identify modifiers of penetrance and age-at-onset of LRRK2 mutations,
respectively. We also investigated whether a polygenic risk score derived from a published genomewide association
study of Parkinson’s disease was able to explain variability in penetrance and age-at-onset in LRRK2 mutation carriers.
Results: A variant located in the intronic region of CORO1C on chromosome 12 (rs77395454; p value = 2.5E-08,
beta = 1.27, SE = 0.23, risk allele: C) met genomewide significance for the penetrance model. Co-immunoprecipitation
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analyses of LRRK2 and CORO1C supported an interaction between these 2 proteins. A region on chromosome 3, within
a previously reported linkage peak for Parkinson’s disease susceptibility, showed suggestive associations in both
models (penetrance top variant: p value = 1.1E-07; age-at-onset top variant: p value = 9.3E-07). A polygenic risk score
derived from publicly available Parkinson’s disease summary statistics was a significant predictor of penetrance, but not
of age-at-onset.
Interpretation: This study suggests that variants within or near CORO1C may modify the penetrance of LRRK2 muta-
tions. In addition, common Parkinson’s disease associated variants collectively increase the penetrance of LRRK2
mutations.
ANN NEUROL 2021;90:76–88
Parkinson’s disease (PD) is the second most commonneurodegenerative disease in older adults.1 Several
genes showing autosomal dominant (SNCA, LRRK2, and
VPS35) or recessive (PRKN, PINK1, and DJ-1) inheri-
tance patterns have been identified as the cause of familial
PD. These genes harbor rare, high penetrance mutations
that explain up to 10% of familial PD cases in different
populations.1,2 Recently, large genomewide association
studies (GWAS) have identified over 90 loci with small
individual effects on disease risk in both familial and spo-
radic PD.3,4
Mutations in LRRK2 are among the most common
genetic causes of PD.1,2 The most frequent mutation is
G2019S (rs34637584), which explains up to 10% of
familial PD cases and 1% to 2% of all PD cases.2,5
Among patients with PD, the frequency of the G2019S
mutation is approximately 3% in Europeans, 16% to
19% in Ashkenazi Jews and up to 42% in Arab-
Berbers.6–15 Estimates of the risk for developing PD
among LRRK2 G2019S mutation carriers range from
15% to 85%.16–19 To explain the incomplete penetrance
of G2019S, it has long been hypothesized that there are
other genes/variants outside of LRRK2 acting to modify its
effect (LRRK2 modifiers). Identification of LRRK2 modi-
fiers could aid the development of novel prevention and
treatment strategies for PD.
Most studies of LRRK2 modifiers, to date, have
focused on candidate genes. Because the protein product
of LRRK2 may interact with α-synuclein (encoded by
SNCA), and tau (encoded by MAPT),20,21 variants in
SNCA and MAPT were widely investigated. However, the
results have been inconsistent, possibly due to small sam-
ple sizes and differences in variants and populations inves-
tigated.22–30 Other PD associated genes, such as GBA,29
BST1,29 GAK,30 and PARK1629,31,32 have also been inves-
tigated. However, the number of studies is limited and
findings remain to be replicated. Genomewide searches for
LRRK2 modifiers are sparse and limited to linkage studies.
Using 85 LRRK2 carriers from 38 families, a genomewide
linkage study of LRRK2 modifiers found a suggestive link-
age region at 1q32 (limit of detection [LOD] = 2.43);
but that study did not identify any candidate genes/
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variants underlying the linkage peak.33 A genomewide
linkage scan in Arab-Berber PD families found DNM3 as
a LRRK2 modifier.34 This finding was not independently
replicated, although it was still significant in a meta-
analysis including the participants reported in the original
finding.25,35 GWASs have successfully detected many dis-
ease genes/variants, including those associated with
PD. However, to date, no GWAS for LRRK2 modifiers
has been reported, probably due to limitations in sample
size and corresponding statistical power.
In this study, we recruited LRRK2 mutation carriers
from multiple centers and performed the first GWAS to
identify genes/variants that modify the penetrance and
age-at-onset of PD among LRRK2 mutation carriers.
Using the largest cohort to date, which consisted of 1,879
LRRK2 mutation carriers (including 776 PD cases), one
genomewide significant association signal was found in
the intronic region of the CORO1C gene. Using co-
immunoprecipitation analyses, we demonstrated that the
protein product of CORO1C interacted with LRRK2. In
addition, we found that a polygenic risk score (PRS)
derived from publicly available PD GWAS summary sta-
tistics, was associated with penetrance, but not age-at-
onset, of PD in LRRK2 mutation carriers.
Methods
Study Participants
The studies and the LRRK2 mutation carriers were
grouped into 3 cohorts. The first cohort was primarily
identified from The Michael J. Fox Foundation’s LRRK2
Consortium and consisted of research sites worldwide
(referred to as the MJFF consortium cohort). We searched
PubMed and identified study groups that reported LRRK2
mutation carriers and then asked them to participate in
this study (PubMed IDs: 16240353, 16333314,
18986508, and 16960813).36–39 We also made
announcements at international conferences to recruit
more study mutation carriers. Details can be found in
their publications.36–39 To maximize participation and
facilitate uniform data preparation across sites, a minimal
dataset was submitted for all subjects that included LRRK2
mutation status, sex, age-at-onset (for PD cases), age at
last evaluation (for non-PD participants), and pedigree
information, along with the availability of a minimal
amount of DNA (approximately 2 ug). The minimal phe-
notypic data were sent to Indiana University and the sub-
jects were assigned a unique identifier. The second cohort
was from Tel Aviv University, Israel (referred to as the
Israel cohort). Participants were of Ashkenazi origin and
recruited from the Movement Disorders Unit at Tel Aviv
Medical Center. PD diagnosis was confirmed by a
movement disorders specialist and clinical disease status
(PD or not diagnosed as PD) was evaluated at the time of
blood draw for genetic testing. The third cohort (referred
to as the 23andMe cohort) consisted of research partici-
pants of the personal genetics company 23andMe, Inc.
who were LRRK2 G2019S carriers and whose PD status
was known. Individuals who reported via an online survey
that they had been diagnosed with PD by a medical pro-
fessional, were asked to provide their age at diagnosis. For
individuals who affirmed at least once that they had not
been diagnosed with PD, their age at the most recent
completion of the survey was recorded. The institutional
review board at each participating site approved this
study.
Genotyping, Quality Review, and Imputation
All study participants were genotyped on the Illumina Omni
2.5 Exome Array version 1.1 (Illumina, San Diego, CA,
USA), except 166 participants from the Israel cohort, who
were genotyped on an earlier version of the same array (ver-
sion 1.0). This array has common, rare, and exonic variants
that were selected from diverse world population samples
included in the 1000 Genomes Project. In total, there were
> 2.58 M variants, including > 567 K exonic variants. Partic-
ipants from the MJFF consortium and 23andMe were gen-
otyped at the Center for Inherited Disease Research (CIDR)
at Johns Hopkins University (Baltimore, MD, USA). The
Israel cohort was genotyped at Tel Aviv University and
2 samples from the MJFF consortium were included for
quality control. There were 134 duplicated and unexpected
identical participants among all 3 cohorts. Pairwise concor-
dance rates were all > 99.97%, showing high consistency
among the 2 genotyping laboratories and the 2 versions of
the Illumina array.
Variants with genotypic missing rates > 5% and
nonpolymorphic variants were excluded. In addition, vari-
ants with A/T or C/G alleles were also excluded due to
strand ambiguity. Hardy–Weinberg equilibrium (HWE)
was not used to filter variants because these participants
were ascertained to be LRRK2 mutation carriers and this
participant selection scheme would directly violate HWE
and remove potential LRRK2 modifiers from the analysis.
To confirm the reported pedigree structure and
detect cryptic relatedness, we used a set of 56,184 high
quality (missing rate < 2%, HWE p values > 0.001), com-
mon (minor allele frequency [MAF] > 0.1), and indepen-
dent (linkage disequilibrium as measured by r2 < 0.5)
variants to calculate the pairwise identity by descent using
PLINK.40 Reported pedigree structures were revised
accordingly, if necessary. Mendelian error checking was
performed in the revised pedigree structure. Any inconsis-
tent genotypes were set to missing. The same set of variants
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was also used to estimate the principal components (PCs) of
population stratification using Eigenstrat.41 All samples
were imputed to the Haplotype Reference Consortium
(http://www.haplotype-reference-consortium.org/) using
Minimac3.42 A total of 725,802 high quality genotyped
variants were selected for imputation (MAF > 3%, HWE
p value > 0.0001, and missing rate < 5%). EAGLE ver-
sion 2.443 was used to phase genotyped variants for each sam-
ple. After filtering out variants with poor imputation quality
score (R2 < 0.6) and checking for Mendelian inconsistencies
using PLINK,40 a final dataset of 7,934,276 imputed and gen-
otyped variants was used for association analyses.
Genomewide Association Studies
Our association analysis tested two models: (1) variants mod-
ifying the penetrance for PD among LRRK2 mutation
carriers (penetrance model), and (2) variants modifying the
age-at-onset for PD among LRRK2 mutation carriers (age-
at-onset model). For the penetrance model (including PD
cases and those not diagnosed as PD at last evaluation), the
association analysis was designed to identify variants associ-
ated with the time to PD diagnosis or last evaluation for
undiagnosed mutation carriers. For the age-at-onset model
(PD cases only), the association analysis tested whether vari-
ants contributed to the age-at-onset for PD cases among
LRRK2 mutation carriers.
For the penetrance model, a mixed effect Cox propor-
tional hazard model (frailty model) was used with sex,
10 PCs, array, and cohort indicators as covariates. Family
relationships were adjusted by using a kinship matrix calcu-
lated using R package COXME (https://cran.r-project.org/
web/packages/coxme/index.html). For the age-at-onset
model, a linear mixed model was fit with the same covariates
as the penetrance model and a kinship matrix to adjust fam-
ily relationships. Although adjusting 10 PCs and family rela-
tionships could minimize the effects of population
stratifications and shared genetic and environment factors
among family members, the use of this mixed samples was
designed to search for common genetic variants that have the
same effects in participants from all populations and could
miss population-specific or family specific findings. Variants
with MAF > 1% were tested for association in these
2 models. In addition to the single variant analyses, we per-
formed gene-based association analyses for both the
TABLE 1. Summary of Study Cohorts
Cohorts MJFF consortium Israel 23andMe Total
Number of participants 768 185 926 1,879
% PD cases (N) 67% (512) 66% (122) 15% (142) 41% (776)
% Females (N) 49% (378) 53% (98) 52% (480) 51% (956)
Mean age at last evaluation (SD) among non-PD 56.2 (15.8) 53.6 (14.3) 45.9 (17.3) 48.7 (17.4)
Mean age at PD diagnosis (SD) among cases 56.9 (12.2) 57.5 (11.4) 59.4 (10) 57.4 (11.7)
LRRK2 mutation (% of total)
G2019S 699 (91%) 185 (100%) 926 (100%) 1810 (96%)
Non-G2019S 69 (9%) N/A N/A 69 (4%)
Families
Number of participants with families (% total) 473 (61%) 96 (52%) 284 (31%) 853 (45%)
Total number of families 138 38 118 294
Average (max) family size 3.4 (17) 2.5 (4) 2.4 (10) 2.9
Average PD ratio in families 0.56 0.43 0.12 0.37
Ancestries (% of total)
European ancestry 91% 100% 89% 91%
Ashkenazi Jewish 37% 100% 48% 49%
African-American or Latinos ancestry 9% 0% 11% 9%
MJFF = Michael J. Fox Foundation; N/A = not applicable; PD = Parkinson’s disease.
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penetrance and age-at-onset models. We focused on rare
exonic and splicing variants, based on annotations from Vari-
ant Effect Predictor (https://useast.ensembl.org/info/docs/
tools/vep/index.html), and restricting to variants with MAF
< 3%. Only genotyped variants (N = 725,802) were used in
the gene-based analyses due to the low quality of imputation
for rare variants. The R package COXME was used to per-
form all analyses (https://cran.r-project.org/web/packages/
coxme/index.html). Conditional analysis was conducted
using the most significant variant in an associated region as a
covariate, and additional signals within the associated region
were determined based on p values < 0.01.
Cell Culture, Co-Immunoprecipitation, and
Antibodies
To test whether the protein product of the identified gene
interacts with LRRK2, we performed co-immunoprecipitation
analyses. HEK293FT (R70007; Invitrogen) cells were
maintained as previously described44 and transiently trans-
fected with pEGFP-C1, pEGFP-CORO1C, or co-transfected
with 3xFlag-LRRK2 using Lipofectamine 2000 (Thermofisher
Scientific) for 16 hours. Cells were washed once with ice cold
PBS and lysed in 1 ml of GFP-trap buffer (20 mM Tris–HCl
pH 7.5, 150 mM NaCl, 1 mM EDTA, 50 mM NaF, 0.3%
Triton X-100, 5% Glycerol, Halt phosphatase inhibitor cock-
tail [Thermofisher Scientific], and protease inhibitor cocktail
[Roche]) or Flag/GFP buffer (20 mM Tris–HCl pH 7.5,
300 mMNaCl, 1 mMEDTA, 50 mMNaF, 0.3% Triton X-
100, 5% Glycerol, Halt phosphatase inhibitor cocktail [Ther-
mofisher Scientific], and protease inhibitor cocktail [Roche])
for 30 minutes on ice, followed by centrifugation at 4C for
10 minutes at 13,900 g to obtain the supernatant. The super-
natant was then incubated with either pre-equilibrated GFP-
Trap agarose beads (ChromoTek) for 1 hour at 4C on an end
over end rotator to recover the GFP tag or pre-cleared with
Pierce Protein A/G Agarose (Thermofisher Scientific;
20 minutes at 4C). Pre-cleared lysates were incubated with
1 μg of monoclonal anti-flag antibody (F3165; Millipore-
Sigma) or rabbit polyclonal anti-GFP (Ab290; Abcam) for
2 hours at 4C on an end over end rotator. Antibody com-
plexes were captured by Protein A/G Agarose beads for
2 hours. Bead complexes were washed 6 times with lysis buffer,
followed by elution in 1 times loading dye containing 2%
β-mercaptoethanol for 6 minutes at 95C. All samples were
resolved by Western blot as previously described.45 Each co-
immunoprecipitation was repeated in 2 to 3 independent
experiments. Primary antibodies used in this study are as fol-
lows: mouse monoclonal anti-FLAG M2 (F3165) was pur-
chased from Thermofisher Scientific; Rabbit polyclonal to
GFP was from Abcam (ab290), and anti-LRRK2 was from
UCDavis/NIHNeuroMab Facility (clone N241A/34).
In Silico Functional Studies
To evaluate whether the genomewide significant findings
had immediate biological consequences on gene expression
FIGURE 1: Manhattan and Q-Q plots of single variant analysis
of penetrance and age-at-onset models. Y-axis is the –log
(p value) for associations. X-axis is physical position of the
variants across the genome. The horizontal line indicates
genome-wide significance. (A) Penetrance model; (B) age-at-
onset model; and (C) Q-Q plots of penetrance model (left)
and age-at-onset model (right).
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(expression quantitative trait locus [eQTL]) of nearby
genes, we searched Open Targets Genetics (https://
genetics.opentargets.org/) and GTEx (https://www.
gtexportal.org/). In addition, protein–protein interaction
(PPI) data were assessed to identify whether the protein
product of the nominated gene either interacts directly
with LRRK2 or has common interactors that are shared
with LRRK2, using Protein Interaction Network Online
Tool (PINOT) version 1.046 queried on June 16, 2020
(http://www.reading.ac.uk/bioinf/PINOT/PINOT_form.
html). We also performed chromatin interaction mapping
to check whether our top findings interact with LRRK2
distantly. Functional Mapping and Annotation of Geno-
meWide Association Studies (FUMA: https://fuma.ctglab.
nl/) was used to perform chromatin interaction map-
ping.47 Hi-C data for chromatin interaction mapping were
from Schmitt et al 2016 and Giusti-Rodriguez et al
2019,48,49 and are available in FUMA.
Polygenic Risk Score Analyses
In the largest GWAS analysis of PD susceptibility to date,
Nalls et al meta-analyzed 17 datasets with 56,306 PD
cases or proxy-cases and 1.4 million controls.4 Based on
their results, they developed a PRS using summary
statistics of 1,805 variants that can explain 26% of PD
heritability.4 In this study, we performed PRS analysis
using these 1,805 variants. Detailed information about
how to select these 1,805 variants was described in Nalls
et al.4 Because we were searching for LRRK2 modifiers,
variants in the LRRK2 region (chr12: 40,118,913-
41,263,086) were excluded. The PRS was calculated as a
weighted summation of effective alleles with the logarithm
of odds ratios as the weights. This derived PRS was used
to fit the same models with the same set of covariates as
described for the genomewide association analyses using
the R package COXME.
Results
Study participants from the 3 cohorts are summarized in
Table 1. In total, 1,879 participants (853 individuals from
294 families and 1,026 singletons) were included in the
analyses. Among them, 776 had, or self-reported, a PD
diagnosis and 1,103 were not classified as affected with
PD at the last evaluation. The majority of participants
were G2019S carriers, only 4% carried other LRRK2
mutations as reported by the contributing sites, all from
the MJFF consortium cohort. In the 23andMe cohort,
85% of participants were not diagnosed with PD and
TABLE 2. Variants That Have P Values < 1.0E-6 in the Penetrance Model
CHR BP rsid Alleles Gene Annotation MAF BETA SE p value
G2019S only
p value
1 221,173,137 rs141686162 A/G HLX, DUSP10 Intergenic 0.01 0.42 0.28 0.13 0.86
3 124,083,400 rs145611031 C/G KALRN Intron 0.02 1.14 0.23 5.2E-07 2.3E-07
3 140,288,373 rs150382576 A/G CLSTN2 3’UTR 0.02 0.78 0.22 5.3E-04 2.1E-03
3 152,841,926 rs59679443 A/G RAP2B,
ARHGEF26
Intergenic 0.04 0.62 0.17 3.1E-04 1.6E-04
3 152,932,435 rs16846845 G/C RAP2B,
ARHGEF26
Intergenic 0.05 0.83 0.16 1.1E-07 4.5E-08
4 160,854,320 rs12272007 A/G LOC107986324 Intergenic 0.01 1.22 0.36 6.0E-04 1.9E-03
5 115,786,384 rs73781088 C/T SEMA6A Intron 0.03 0.47 0.19 0.01 0.05
8 9,520,115 rs28398294 G/A TNKS Intron 0.03 1.09 0.22 5.7E-07 1.1E-06
9 127,532,973 rs148922482 C/T NR6A1 Intron 0.01 0.90 0.28 1.4E-03 3.7E-03
11 120,585,515 rs28470321 G/A GRIK4 Intron 0.01 1.91 0.36 9.0E-08 6.1E-08
12 109,080,567 rs77395454 C/T CORO1C Intron 0.02 1.27 0.23 2.5E-
08
1.0E-06
14 90,982,388 rs76788674 A/G CALM1, TTC7B Intergenic 0.03 0.78 0.16 7.1E-07 2.8E-06
X 123,652,525 rs185981774 A/G TENM1 Intron 0.02 0.86 0.17 5.4E-07 3.9E-07
Note: Genomewide significant variant is in bold.
CHR = chromosome; MAF = minor allele frequency.
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most of them were less than 50 years of age at the time of
their last evaluation. Based on PCs, the majority of partici-
pants were of European ancestry.
Manhattan plots for the single variant analyses of the
penetrance and age-at-onset models are shown in Figure 1A
and 1B. Q-Q plots for both models are show in Figure 1C.
No obvious bias was detected in either model; and genomic
controls were 1.055 and 1.052 for the penetrance model
and age-at-onset model, respectively. Twelve loci showed
variants with p values < 1.0E-6 (ie, meet the threshold for
suggestive significance) in either the penetrance model or
the age-at-onset model (Supplementary Table S1). One var-
iant on chromosome 12 reached genomewide significance
(rs77395454, p value = 2.5E-08) in the penetrance model
(Table 2, Supplementary Table S1). Conditional analysis
suggested that there were no additional association signals
in this locus. The top variant (rs77395454) on the chromo-
some 12 region is located in an intron of CORO1C
(coronin 1C; Fig 2). The causal haplotype(s) spanned
SELPLG, CORO1C, and SSH1, with most of the variants
within CORO1C. Figure 3A–C shows the survival curves
stratified by rs77395454 genotypes for all samples, familial
samples, and unrelated samples, respectively. Heterozygous
rs77395454 carriers (20 familial and 37 unrelated samples)
had an increased risk of PD. Six other loci met suggestive
significance (p value < 1.0E-6) for the penetrance model
(see Table 2).
For the age-at-onset model, no chromosomal region
reached genomewide significance, but 7 loci met the sug-
gestive association threshold. Except for variants on chro-
mosome 3 identified in both models, rs73781088 on
chromosome 5 (intron of SEMA6A) for the age-at-onset
model and rs28398284 on chromosome 8 (intron of
TNKS) for the penetrance model, all other variants had no
or marginal LD support. Variants on chromosome 3 from
both models cover the same region but identified different
haplotypes.
For comparison purposes, we also performed analyses
limited to only the LRRK2 G2019S carriers; overall the
results were comparable (see Table 2, Supplementary
Table S1) but rs16846845 on chromosome 3 (p value
= 4.5E-08) was genomewide significant for the penetrance
model. In addition, we performed analyses using only indi-
viduals of predicted Ashkenazi Jewish ancestry. Results are
less significant due to dramatically decreased sample sizes as
shown in Supplementary Table S2. No genomewide
FIGURE 2: Regional association plot of the chromosome 12 region for the penetrance model. Y-axis is the –log
(p value) for associations. X-axis denotes physical positions on the chromosome (Mb). The color scale shows the extent
of linkage disequilibrium (LD; as measured by r2) between each variant and the top variant (indicated by the purple
diamond) with larger r2 indicating greater LD. Peaks indicate the recombination hot spots. SNP = single nucleotide
polymorphism.
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significant results were detected in the gene-based analysis
using exonic variants for either model.
We next sought evidence of a physical interaction
between CORO1C and LRRK2 using co-immunopre-
cipitation analyses. GFP-tagged CORO1C or eGFP empty
vector control were transfected into HEK293FT and
lysates were incubated with anti-GFP agarose beads to
recover the GFP tag; relative to empty vector control,
eGFP-CORO1C co-precipitated endogenous LRRK2
from HEK293FT cells (Fig 4A). To further support this
interaction, 3xFlag-tagged LRRK2 with either GFP-tagged
CORO1C or eGFP empty vector control were
cotransfected into HEK293FT and, after 16 hours, lysates
were incubated with anti-GFP or anti-Flag antibodies to
immunoprecipitate the GFP or Flag tag, respectively.
Immunoprecipitation of LRRK2 via the Flag antibody co-
precipitated eGFP-CORO1C, but not the eGFP from the
empty vector control. (Fig 4B). Reciprocally, immunopre-
cipitation of the GFP tag via a GFP antibody co-
precipitated Flag-LRRK2 only in the presence of GFP-
CORO1C but not the empty vector GFP control
(Fig 4C). Thus, co-immunoprecipitation analysis of Flag-
LRRK2 and GFP-CORO1C support an interaction
between these 2 proteins.
By searching Open Targets Genetics and GTEx, we
found that the most significant variant, rs77395454, is an
eQTL of CORO1C in blood and MYO1H in visceral adi-
pose (omentum) but not in any brain tissues. The minor
allele (C allele) is associated with higher expression of
CORO1C and MYO1H. We did not find any previous
report that LRRK2 interacts with CORO1C or MYO1H
directly, however, there are several proteins that are the com-
mon interactors of both LRRK2 and CORO1C: ABCE1,
ACTR2, CDC42, DAPK1, MYO1C, RAC1, and TP53, as
identified by using PINOT,46 and it remains to be deter-
mined whether the interaction of LRRK2 with CORO1C
is within a single complex or dependent upon these com-
mon interacting proteins. Chromatin interaction mapping
did not find any variant that interacts with LRRK2
distantly.
Among those 1,805 variants that were obtained
from the study of Nalls et al 2019,4 20 variants were
not present in our datasets. An additional 27 variants
were located in the LRRK2 region and were excluded,
and 1,758 variants were included in the PRS calcula-
tion. The PRS was a significant predictor in the pene-
trance model (p value = 7.8E-4) but not in the age-at-
onset model (p value = 0.75). These results suggest that
a high genetic risk of PD significantly increases the
chance of developing PD among LRRK2 mutation
carriers.
FIGURE 3: Cumulative incidence of PD stratified by
rs77395454 genotypes. Dashed lines indicate 95%
confidence interval. Due to the low MAF of rs77395454 and
therefore the small number of CC genotype carriers, only
participants with TT and CT genotypes are shown. (A) All
samples; (B) familial samples; and (C) unrelated samples.
MAF = minor allele frequency; SNP = single nucleotide
polymorphism.
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Discussion
Two major unresolved questions in PD research are why
some, but not all, LRRK2 mutation carriers develop PD,
and why the age-at-onset is so variable in those that
do. This work represents the first GWAS study to report
LRRK2 modifiers of PD penetrance and age-at-onset. One
variant on chromosome 12 reached genomewide signifi-
cance in the penetrance model (rs77395454 in an intronic
region of CORO1C). Several loci reached suggestive signif-
icance in either the penetrance model or the age-at-onset
model. One region on chromosome 3 showed suggestive
associations in both models and reached genomewide sig-
nificance in penetrance model when focused on G2019S
carriers only. PRS derived from a publicly available PD
GWAS was a significant predictor of penetrance of
PD among LRRK2 mutation carriers.
The genomewide significant variant, rs77395454 on
chromosome 12, is located in an intronic region of
CORO1C. Our co-immunoprecipitation experiments from
HEK293 cells found LRRK2 interacted with CORO1C.
In addition, there also are several proteins that are com-
mon interactors of both LRRK2 and CORO1C. Two of
them, CDC42 and RAC1, have previously been validated
as modifiers of LRRK2-mediated neurite shortening
(reviewed in Boon et al 2014),50 suggesting that both
CORO1C and LRRK2 might have effects on the actin
cytoskeleton. Furthermore, a recent APEX2 screen identi-
fied that CORO1C is physically proximate to LRRK2 in
cells.51 Notably, the protein expression of Coro1c is signif-
icantly higher in Lrrk2 knockout mice in vivo, as shown
by proteomics and validated by Western blotting.52 The
accumulation of CORO1C in knockout mice might rep-
resent compensation for diminished LRRK2 function.
The CORO1C protein is a member of the WD repeat
protein family that has been implicated in signal transduc-
tion, gene regulation (https://www.ncbi.nlm.nih.gov/gene/
23603). In a zebrafish model of spinal muscular atrophy,
overexpression of CORO1C rescued the phenotype caused
by SMN deficiency.53 Using mass spectrometry, Malty et al
showed that the product of CORO1C interacts with
mitochondrial proteins associated with neurodegeneration.54
Collectively, these complementary results support that
CORO1C is a more likely functional interactor of LRRK2
and all of these warrant more in-depth cell and in vitro stud-
ies, including mapping the domains of LRRK2 responsible
for the interaction between LRRK2 and CORO1C. How-
ever, it is possible that other genes in this region may under-
pin the observed association. For example, the protein
product of SSH1 regulates actin filament dynamics, which
has been linked to LRRK2 mutations.55,56 SELPLG has been
linked to neuropsychiatric disorders, such as conduct disor-
der.57 Further studies are needed to conclusively determine
the gene(s) underlying the observed association.
Multiple variants on chromosome 3 were supported
by both models, although they identified different associ-
ated haplotypes. The most significant variants were
rs16846845 in the penetrance model and rs150382576 in
the age-at-onset model. Furthermore, rs16846845 reached
genomewide significance in G2019S only analysis for pen-
etrance model. This region is under a known linkage peak
FIGURE 4: Evidence of a LRRK2-CORO1C complex. (A) Immunoprecipitation (IP) analysis of lysates from HEK293FT cells
transiently expressing eGFP-C1 empty vector control or eGFP-CORO1C. IP with GFP-Trap was followed with immunoblot
analysis with an anti-GFP (bottom panel) or an anti-LRRK2 antibody (top panel) as indicated. Input denotes whole cell lysate
material that was used for immunoprecipitation analysis. (B, C) Co-immunoprecipitation analysis of lysates from HEK293FT cells
transiently co-expressing 3xflag (3FL) epitope-tagged LRRK2 with either eGFP-C1 empty vector control or eGFP-CORO1C.
Epitope-tagged proteins were recovered from lysates using anti-Flag (IP: Flag) or anti-GFP (IP: GFP) antibodies, followed by
immunoblot detection using anti-Flag (top panels) and anti-GFP (bottom panels) antibodies. Input denotes whole cell lysate
starting material from HEK293FT cells used for immunoprecipitation analysis; +/ indicates cDNA transfections.
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for PD (LOD = 2.5).58 In the study by Gao et al, 2 vari-
ants (rs902432 and rs755763) had LOD scores > 2 in dif-
ferent analysis models.58 These 2 variants are about
850 Kb upstream and 200 Kb downstream from variants
identified in our study, respectively. This is consistent
with our findings that top variants in either model, and
variants in LD with them, were physically distinct from
each other. A nearby region was also linked to PD
(LOD = 3.6) in an Amish Parkinsonism pedigree linkage
study performed by Lee et al.59 In both Gao et al and Lee
et al linkage studies, no candidate genes were nominated
due to the large size of the reported linkage regions.58,59
Variants that we identified are not located in any gene
and the nearest gene is RAP2B, a member of the RAS
oncogene family. However, its role in PD is unknown.
Rs73781088 on chromosome 5 is in the intronic
region of SEMA6A, which is broadly expressed in the brain.
This gene is associated with amyotrophic lateral sclerosis.60
Rs28398294 on chromosome 8 is in the intronic region of
TNKS, which is also broadly expressed in the brain. This
region has been linked to Alzheimer’s disease.61
Rs141686162 on chromosome 1 is in an intergenic region
near DUSP10, which has been associated with progressive
supranuclear palsy in a recent study.62 All of these findings
warrant further study to investigate their potential roles in
modifying the effect of LRRK2mutations.
We also examined the variants previously reported as
LRRK2 modifiers in other studies. Thirteen variants from
7 genes passed our QC (rs4273468 from BST1; rs2421947
from DNM3; rs1564282 from GAK; rs1052553, rs242562,
and rs2435207 from MAPT; rs823144 from PARK16;
rs11931074, rs1372525, rs181489, rs2583988, and rs356219
from SNCA; rs11578699 fromVAMP4).20–32,34,35Only 4 var-
iants from 3 genes had p values < 0.05: rs823144 from
PARK16 in the penetrance model (p value= 0.01); rs1564282
fromGAK in both the penetrance (p value= 0.03) and age-at-
onset models (p value = 7.1E-03); rs2345207 (p value
= 5.1E-04); and rs1052553 (p value = 0.02) from MAPT in
the penetrance model. Unfortunately, because some individ-
uals in our study may have also been included in previous stud-
ies where these candidate genes were first reported, our
findings do not represent independent replication. However,
our results showed that previously reported variants in BST1,
DNM3, SNCA, and VAMP4 were not replicated, and whether
they are LRRK2modifiers remains equivocal.
The significant effect of the PRS in the penetrancemodel
supports the polygenic nature of the LRRK2 modifiers (ie,
there are many genetic variants each with a small effect that col-
lectively have a significant effect on the risk of PD in LRRK2
mutation carriers). This result is in line with the recent analysis
of Iwaki et al.63 In that study, a PRS was derived using
89 genomewide significant variants (some variants were also
included in our PRS) identified in a PD GWAS of Nalls et al.4
Iwaki et al found that the PRS was significantly associated with
LRRK2 G2019S penetrance. Potential overlap between the
participants in our study and that of Iwaki et al means that the
results of these studies do not represent independent replica-
tion. We did not detect a significant association in the age-at-
onset model. One reason for this may be the smaller sample
size (less than half of that in the penetrance model, only
776 affected from 1,879 total participants analyzed), and the
resulting lack of statistical power. Another possible explanation
is that the PRS was derived from aGWAS comparing PD cases
and controls, and these risk-associated genes/variants are not
necessarily associated with age-at-onset. Note, some partici-
pants of our study were included in the study of Nalls et al.4
Although we were unable to directly check for overlapping
samples and the results were potentially biased, the overlapping
samples is at most 0.13% of the total sample in Nalls et al,
therefore, our samples had a minimal influence on the weight
estimation that was used to calculate the PRS.
There are several limitations of this study. First, despite
the effort to enroll as many participants as possible, the sample
size of this study still resulted in only modest statistical power.
With this sample size, assuming a linear model, for a variant
with MAF 3%, a change of at least 6 years of age-at-onset can
be detected with 80% power at a genomewide significant level.
Second, to maximize the number of eligible studies to join this
collaboration, our inclusion criteria was quite minimal.
Although this approach dramatically increased the sample size,
many potentially important covariates were not collected and
could not be adjusted for in subsequent analyses. Third,
approximately 96% of our participants were G2019S carriers.
However, there are carriers of other LRRK2 mutations in the
MJFF cohort. Although in a sensitivity analysis using only
G2019S carriers, we observed similar effects for those top vari-
ants that we identified in both models, these mutations may
have different effects that cannot be detected in the small num-
ber of carriers. Fourth, our study cohorts consisted of family
participants and unrelated participants. Family history was not
collected for every participant. Therefore, some unrelated indi-
viduals may be sporadic PD and have different penetrance
from familial PD participants. Fifth, there was a lack of infor-
mation on subjects with subtle signs of PD but who did not
yet merit a diagnosis of PD. Sixth, although we included
10 PCs to adjust population stratifications, there may still exist
fine-scale population stratifications that cannot be detected by
those 10 PCs thus could potentially cause false positive find-
ings. Nevertheless, we detected a genomewide significant vari-
ant. We provide experimental data to show CORO1C and
LRRK2 interact, and support that observation by proteomics
literature. The PRS analysis suggested that there is unlikely to
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be one or several single LRRK2modifiers, but similar to overall
PD risk, penetrance of LRRK2 mutations is affected by multi-
ple genetic variants. Given the significant therapeutic efforts
underway to develop targets for patients with PD carrying
LRRK2 mutations, further replication of these results is essen-
tial. Furthermore, the genetic variants identified in this study
and the PRS evaluated in the LRRK2mutation carriers, may be
used in the future to make personalized prevention and treat-
ment possible.
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